The PE Ratio as of May 2025 (TTM) for Provectus Biopharmaceuticals, Inc. (PVCT) is -8.30

According to Provectus Biopharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.30. This represents a change of -18.85% compared to the average of -10.23 of the last 4 quarters.

Provectus Biopharmaceuticals, Inc. (PVCT) Historical PE Ratio (quarterly & annually)

How has PVCT PE Ratio performed in the past?

The mean historical PE Ratio of Provectus Biopharmaceuticals, Inc. over the last ten years is -5.34. The current -8.30 PE Ratio has changed 15.45% with respect to the historical average. Over the past ten years (40 quarters), PVCT's PE Ratio was at its highest in in the December 2016 quarter at -0.22. The PE Ratio was at its lowest in in the March 2024 quarter at -39.56.

Provectus Biopharmaceuticals, Inc. (PVCT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Provectus Biopharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Provectus Biopharmaceuticals, Inc. (PVCT) Average PE Ratio

How has PVCT PE Ratio performed in the past?

The current PE Ratio of Provectus Biopharmaceuticals, Inc. (PVCT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Provectus Biopharmaceuticals, Inc. (PVCT) PE Ratio vs. Peers

How is PVCT’s PE Ratio compared to its peers?

Provectus Biopharmaceuticals, Inc.’s PE Ratio is less than Aerovate Therapeutics, Inc. (0), less than Celldex Therapeutics, Inc. (-7.59), greater than Kiniksa Pharmaceuticals, Ltd. (-112.51), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Crinetics Pharmaceuticals, Inc. (-8.86), less than Ikena Oncology, Inc. (0), less than Xilio Therapeutics, Inc. (-1.28), less than Protara Therapeutics, Inc. (-1.56), less than Scholar Rock Holding Corporation (-2.86), greater than Vaccitech plc (-12.93), less than Acurx Pharmaceuticals, Inc. (-0.58), less than NervGen Pharma Corp. (-0.00), greater than NeuBase Therapeutics, Inc. (-13.69), less than Cyclacel Pharmaceuticals, Inc. (-0.20), less than Axcella Health Inc. (-0.65), less than Century Therapeutics, Inc. (-0.12), less than Kezar Life Sciences, Inc. (-2.20), less than Mineralys Therapeutics, Inc. (-0.38), less than Nkarta, Inc. (-4.33), less than NGM Biopharmaceuticals, Inc. (-1.16), less than null (-1.35),

Build a custom stock screener for Provectus Biopharmaceuticals, Inc. (PVCT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Provectus Biopharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Provectus Biopharmaceuticals, Inc. (PVCT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Provectus Biopharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.